Top Page
Zhong Ji Longevity Science Group Limited
(0767)
Zhong Ji Longevity Science Group Limited (0767) vs. iShares MSCI Hong Kong ETF (EWH)
Zhong Ji Longevity Science Group Limited Business Overview & Revenue Model
Zhong Ji Longevity Science Group Limited Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 174.06M | 168.63M | 64.99M | 89.44M | 62.98M | 81.41M |
| Gross Profit | 174.06M | 57.41M | 56.28M | 79.41M | 49.40M | 71.83M |
| EBITDA | -17.56M | -29.96M | 13.02M | 15.99M | 16.13M | -11.89M |
| Net Income | -46.43M | -34.73M | 2.31M | -904.00K | 6.05M | -11.49M |
Balance Sheet | ||||||
| Total Assets | 509.39M | 525.63M | 509.25M | 484.84M | 517.50M | 478.24M |
| Cash, Cash Equivalents and Short-Term Investments | 30.04M | 47.84M | 81.08M | 60.07M | 19.44M | 40.80M |
| Total Debt | 12.77M | 19.11M | 20.20M | 11.76M | 12.93M | 8.70M |
| Total Liabilities | 77.85M | 125.49M | 78.79M | 63.99M | 46.78M | 23.35M |
| Stockholders Equity | 404.98M | 373.42M | 403.40M | 393.83M | 443.75M | 428.83M |
Cash Flow | ||||||
| Free Cash Flow | -106.77M | -61.76M | 15.28M | 11.08M | -40.51M | -192.89M |
| Operating Cash Flow | -104.97M | -61.05M | 15.28M | 12.11M | -39.62M | -191.54M |
| Investing Cash Flow | 10.45M | 11.47M | 382.00K | 16.59M | 2.91M | 70.11M |
| Financing Cash Flow | 20.18M | 15.17M | 6.02M | -7.45M | 3.44M | -1.43M |
Zhong Ji Longevity Science Group Limited Technical Analysis
Zhong Ji Longevity Science Group Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | HK$332.00M | 6.78 | 5.24% | 5.63% | -1.47% | 2.86% | |
| ― | HK$342.20M | 6.42 | 2.75% | 4.79% | -12.94% | -15.93% | |
| ― | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% | |
| ― | HK$333.11M | 11.45 | 1.12% | ― | -9.75% | -81.16% | |
| ― | HK$226.60M | 7.54 | 4.83% | ― | -25.74% | ― | |
| ― | HK$331.06M | ― | -11.40% | ― | 121.54% | -8360.00% |
Zhong Ji Longevity Science Group Limited Corporate Events
Zhong Ji Longevity Science Group Limited announced supplemental information related to its 2024 Annual Report, detailing the use of net proceeds from a subscription. The company fully utilized approximately HK$19.4 million, with 60% allocated to expanding its longevity science and biomedical products trading businesses, and 40% for general working capital. No share options were granted under the 2022 Share Option Scheme during the fiscal year 2024.
The most recent analyst rating on (HK:0767) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on Zhong Ji Longevity Science Group Limited stock, see the HK:0767 Stock Forecast page.
Zhong Ji Longevity Science Group Limited announced the resignation of Mr. Yan Yifan and Ms. Cao Xie Qiong from their executive director roles, with Mr. Yan also stepping down as CEO to focus on personal commitments. Mr. Yan Li, an experienced executive in the medical technology field and already serving as the company’s chairman, has been appointed as the new CEO. This leadership change may impact the company’s strategic direction and operational focus, as Mr. Yan Li brings significant expertise in biotechnology and management.
Zhong Ji Longevity Science Group Limited has announced the composition of its board of directors and the roles within its five board committees. This announcement outlines the leadership structure, which includes executive, non-executive, and independent non-executive directors, and highlights the company’s commitment to strong governance and strategic oversight.
Zhong Ji Longevity Science Group Limited announced a collaboration agreement between its subsidiary, Zhongli (Hainan) Life Science Technology Co., Ltd., and Hainan Boao Super Hospital Co., Ltd. to establish the International Precision Oncology Medical Center. This collaboration aims to leverage Hainan Boao’s advanced medical facilities and Zhongli’s expertise in longevity health services to provide comprehensive diagnostic and treatment services. The partnership is expected to enhance the company’s positioning in the health and longevity science market, capitalizing on the growing demand for innovative health solutions.
Zhong Ji Longevity Science Group Limited has announced an extension of the expiry date for its Memorandum of Understanding (MOU) regarding the potential acquisition of Asian Integrated Cell Laboratory Limited. This extension, until December 2, 2025, allows more time for due diligence and assessment. The target company collaborates with Bright Cells Inc. to conduct FDA-approved clinical research on stem cells, aiming to develop treatments for aging-related frailty and premature ovarian failure across various regions. The acquisition, if completed, could significantly impact the company’s market position and stakeholder interests.
Zhong Ji Longevity Science Group Limited announced its interim results for the first half of 2025, revealing a 13.1% increase in revenue to HK$48.0 million compared to the previous year. Despite the revenue growth, the company faced a significant decrease in gross profit by 51.8% and recorded a loss before tax of approximately HK$11.5 million. The company’s net assets, however, increased by 7.9% to HK$431.5 million. No interim dividend was recommended for the period.
Zhong Ji Longevity Science Group Limited has announced a board meeting scheduled for August 28, 2025, to consider and approve the interim results for the first half of 2025 and discuss the potential payment of an interim dividend. This meeting is a significant event for the company as it will address key financial outcomes and strategic decisions that could impact stakeholders and the company’s market position.
Zhong Ji Longevity Science Group Limited announced a memorandum of cooperation between its subsidiary, Blooming Faith Development Limited, and Shenzhen Zhonghang Health and Fashion Group Co., Ltd. This collaboration aims to enhance their offerings in the longevity testing and management sector, leveraging Blooming Faith’s product and management expertise and Zhonghang Health’s customer resources and marketing channels. The partnership is expected to strengthen the company’s position in the growing health and longevity science market, which is increasingly attracting affluent consumers worldwide.
Zhong Ji Longevity Science Group Limited announced the withdrawal of a winding-up petition against the company, following approval from the Hong Kong court. This development may have implications for the company’s stakeholders, as it alleviates immediate legal pressures and could stabilize investor confidence.
Zhong Ji Longevity Science Group Limited has announced a non-legally binding memorandum of understanding to potentially acquire Asian Integrated Cell Laboratory Limited from China International Osteoarticular Medical Group Limited. This acquisition would enhance Zhong Ji’s capabilities in cell management and transformation, as the target company is a leading platform in the global market, holding the largest international autoimmune cell bank and being the only dual-type full-system clinical cell bank registered by the US FDA in Asia.
Zhong Ji Longevity Science Group Limited is currently involved in legal proceedings concerning convertible notes issued during its 2015 acquisition of the Caijia P2P financing loans platform. Harmony Delight has filed a claim against the company, seeking either the conversion of these notes into shares or a monetary sum. The company is seeking legal advice to address concerns about the legality and validity of the convertible notes, citing potential issues such as the illegality of the acquired business, breach of profit guarantees, and possible fraudulent activities.
Zhong Ji Longevity Science Group Limited announced a memorandum of cooperation between its subsidiary, Blooming Faith Development, and Haoshiduo (Shenzhen) Biotechnology Co., Ltd. This collaboration aims to enhance the company’s offerings in longevity testing and management by leveraging Haoshiduo’s domestic customer resources and marketing channels. The partnership aligns with the company’s strategy to expand its presence in the longevity science market, potentially leading to new revenue streams and sustained growth.
Zhong Ji Longevity Science Group Limited has announced a clarification regarding a winding up petition that was previously filed against the company. The petitioner has agreed to withdraw the petition, and it has been confirmed that this development will not impact the company’s business operations or financial position. The company will continue to update shareholders and potential investors on any further progress.